

Sabino De Placido

List of Publications by Citations

Source: <https://exaly.com/author-pdf/37175/sabino-de-placido-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

191
papers

5,943
citations

43
h-index

70
g-index

212
ext. papers

7,347
ext. citations

5.2
avg, IF

5.37
L-index

#	Paper	IF	Citations
191	Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. <i>Journal of Clinical Oncology</i> , 2008 , 26, 44-53	2.2	327
190	Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 396-405	21.7	271
189	Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. <i>Journal of Clinical Oncology</i> , 2015 , 33, 910-5	2.2	262
188	Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 2526-34	6.1	165
187	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. <i>Breast Cancer Research</i> , 2011 , 13, R67	8.3	161
186	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet</i> , 2019 , 393, 1440-1452	40	137
185	Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. <i>Lancet</i> , 2015 , 385, 1863-72	40	131
184	A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, 1113-9	4	125
183	Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4469-74	2.2	114
182	Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. <i>Cancer Research</i> , 2018 , 78, 845-852	10.1	111
181	Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. <i>European Urology</i> , 2008 , 54, 1089-94	10.2	106
180	CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. <i>Frontiers in Oncology</i> , 2018 , 8, 608	5.3	106
179	Mechanisms of lapatinib resistance in HER2-driven breast cancer. <i>Cancer Treatment Reviews</i> , 2015 , 41, 877-83	14.4	85
178	First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2826-2835	2.2	82
177	What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO) 2016 , 4,		78
176	Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. <i>Clinical Cancer Research</i> , 2013 , 19, 138-47	12.9	77
175	Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. <i>Breast Cancer Research</i> , 2014 , 16, 440	8.3	77

174	Castration-resistant prostate cancer: current and emerging treatment strategies. <i>Drugs</i> , 2010 , 70, 983-1000	10.0	77
173	High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. <i>Breast</i> , 2014 , 23, 69-75	3.6	72
172	Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. <i>BJU International</i> , 2011 , 107, 234-9	5.6	71
171	Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. <i>Oncologist</i> , 2017 , 22, 601-608	5.7	70
170	2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. <i>European Heart Journal Cardiovascular Imaging</i> , 2017 , 18, 930-936	4.1	70
169	A comprehensive outlook on intracerebral therapy of malignant gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 80, 54-68	7	70
168	Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. <i>Cancer</i> , 2008 , 112, 75-83	6.4	70
167	Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2018 , 36, 342-349	2.2	70
166	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology, The</i> , 2019 , 20, 1360-1369	21.7	68
165	Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going. <i>Cancer Treatment Reviews</i> , 2016 , 46, 20-6	14.4	66
164	Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. <i>Cancer Treatment Reviews</i> , 2019 , 73, 73-83	14.4	62
163	Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1207-13	3.5	58
162	Gene expression profiling in breast cancer: a clinical perspective. <i>Breast</i> , 2013 , 22, 109-120	3.6	56
161	Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study. <i>Menopause</i> , 2016 , 23, 1108-13	2.5	55
160	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 1	7.8	54
159	Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. <i>Cancer Treatment Reviews</i> , 2016 , 50, 129-141	14.4	52
158	Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. <i>British Journal of Cancer</i> , 2017 , 116, 1425-1435	8.7	50
157	Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. <i>Breast Cancer Research</i> , 2014 , 16, R45	8.3	49

156	Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. <i>European Urology</i> , 2011 , 60, 1280-4	10.2	48
155	Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. <i>European Urology</i> , 2010 , 58, 906-11	10.2	48
154	Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. <i>BJU International</i> , 2012 , 110, E661-6	5.6	47
153	Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. <i>Breast Cancer Research</i> , 2008 , 10, R60	8.3	47
152	Analysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients. <i>BioMed Research International</i> , 2014 , 2014, 840921	3	46
151	Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. <i>Oncology</i> , 2009 , 77 Suppl 1, 23-37	3.6	44
150	Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 1578-80	4.3	44
149	Features of aggressive breast cancer. <i>Breast</i> , 2015 , 24, 594-600	3.6	43
148	Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. <i>Menopause</i> , 2018 , 25, 657-662	2.5	43
147	Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. <i>Breast</i> , 2017 , 31, 114-120	3.6	42
146	Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. <i>Cancer Treatment Reviews</i> , 2015 , 41, 61-8	14.4	42
145	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020 , 84, 101965	14.4	39
144	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 474-485	21.7	39
143	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience. <i>Medicine (United States)</i> , 2015 , 94, e1861	1.8	39
142	The emerging role of obesity, diet and lipid metabolism in prostate cancer. <i>Future Oncology</i> , 2017 , 13, 285-293	3.6	37
141	Imatinib mesylate in thymic epithelial malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 309-15	3.5	35
140	Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell-Renal Cell Carcinoma. <i>Medicine (United States)</i> , 2015 , 94, e2117	1.8	34
139	Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. <i>Scientific Reports</i> , 2017 , 7, 9388	4.9	33

138	Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction. <i>European Heart Journal Cardiovascular Imaging</i> , 2019 , 20, 1345-1352	4.1	33
137	Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs. <i>BioMed Research International</i> , 2015 , 2015, 138148	3	32
136	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. <i>European Journal of Cancer</i> , 2017 , 71, 34-42	7.5	31
135	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017 , 82, 237-246	7.5	30
134	Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status. <i>Oncotarget</i> , 2015 , 6, 26090-103	3.3	30
133	Cytometric and biochemical characterization of human breast cancer cells reveals heterogeneous myoepithelial phenotypes. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012 , 81, 960-72	4.6	28
132	New perspectives in the therapy of castration resistant prostate cancer. <i>Current Drug Targets</i> , 2012 , 13, 1676-86	3	28
131	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019 , 474, 421-432	5.1	28
130	Biomarkers in localized prostate cancer. <i>Future Oncology</i> , 2016 , 12, 399-411	3.6	27
129	Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. <i>Molecular Cancer Research</i> , 2016 , 14, 470-81	6.6	27
128	Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 534-41	7	27
127	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2013 , 9, 889-97	3.6	27
126	Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 127-32	4.4	26
125	Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2011 , 129, 451-8	4.4	26
124	Combination of docetaxel and cetuximab for penile cancer: a case report and literature review. <i>Anti-Cancer Drugs</i> , 2012 , 23, 573-7	2.4	26
123	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 1089-1097	9.7	25
122	Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. <i>Journal of Translational Medicine</i> , 2013 , 11, 161	8.5	25
121	Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer. <i>Oncology</i> , 2010 , 78, 369-75	3.6	25

120	Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study. <i>Cancer</i> , 2008 , 112, 1147-52	6.4	25
119	Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. <i>World Journal of Gastroenterology</i> , 2010 , 16, 2526-30	5.6	25
118	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 548-555.e3	3.3	24
117	Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBEO phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019 , 118, 178-186	7.5	23
116	Approaches for targeting cancer stem cells drug resistance. <i>Expert Opinion on Drug Discovery</i> , 2016 , 11, 1201-1212	6.2	23
115	Peg-filgrastim and cabazitaxel in prostate cancer patients. <i>Anti-Cancer Drugs</i> , 2013 , 24, 84-9	2.4	22
114	Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 1455-61	3.5	22
113	Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis. <i>BMC Cancer</i> , 2016 , 16, 375	4.8	22
112	Multiple treatment lines and prognosis in metastatic colorectal cancer patients. <i>Cancer and Metastasis Reviews</i> , 2019 , 38, 307-313	9.6	21
111	Targeting bone metastatic cancer: Role of the mTOR pathway. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1845, 248-54	11.2	21
110	Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2014 , 10, 1353-60	3.6	21
109	Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. <i>Breast</i> , 2018 , 38, 86-91	3.6	20
108	Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom?. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 185-91	3.8	20
107	Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 147-54	4.4	20
106	An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1491-7	4	20
105	Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020 , 12,	6.6	19
104	Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. <i>Cancers</i> , 2019 , 11,	6.6	19
103	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. <i>ClinicoEconomics and Outcomes Research</i> , 2013 , 5, 125-35	1.7	19

102	Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 66, 171-80	7	19
101	Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients. <i>Cancer</i> , 2009 , 115, 517-23	6.4	18
100	Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , 2020 , 5,	6	18
99	PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom?. <i>Breast Care</i> , 2017 , 12, 290-294	2.4	17
98	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. <i>Oncotarget</i> , 2018 , 9, 19861-19873	3.3	17
97	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. <i>Future Oncology</i> , 2015 , 11, 3091-8	3.6	16
96	Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. <i>BMC Cancer</i> , 2013 , 13, 164	4.8	16
95	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1387-1401	5.4	16
94	Fast Detection of a BRCA2 Large Genomic Duplication by Next Generation Sequencing as a Single Procedure: A Case Report. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	15
93	Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. <i>European Urology Focus</i> , 2018 , 4, 874-879	5.1	15
92	FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience. <i>Anti-Cancer Drugs</i> , 2013 , 24, 980-5	2.4	15
91	Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports. <i>World Journal of Clinical Cases</i> , 2014 , 2, 228-31	1.6	15
90	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , 2019 , 24, 385-393	5.7	15
89	Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study. <i>Frontiers in Pharmacology</i> , 2016 , 7, 487	5.6	14
88	Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study. <i>Medicine (United States)</i> , 2015 , 94, e2297	1.8	13
87	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021 , 149, 134-152	7.5	13
86	Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. <i>Medicine (United States)</i> , 2016 , 95, e2299	1.8	13
85	Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019 , 11,	6.6	12

84	Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 669-78	4.9	12
83	Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial. <i>Frontiers in Pharmacology</i> , 2018 , 9, 189	5.6	12
82	Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer. <i>Annals of Nuclear Medicine</i> , 2019 , 33, 937-944	2.5	12
81	EGFR mutational status in penile cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2013 , 17, 501-5	6.4	12
80	Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. <i>Breast</i> , 2013 , 22, 470-5	3.6	12
79	Everolimus induces Met inactivation by disrupting the FKBP12/Met complex. <i>Oncotarget</i> , 2016 , 7, 40073-40084	3.9	12
78	The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer 2016 , 4,		11
77	Combined imaging with 18F-FDG-PET/CT and 111In-labeled octreotide SPECT for evaluation of thymic epithelial tumors. <i>Clinical Nuclear Medicine</i> , 2013 , 38, 354-8	1.7	11
76	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. <i>Tumori</i> , 2011 , 97, 690-2	1.7	11
75	Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study. <i>Oncotarget</i> , 2017 , 8, 115709-115717	3.3	11
74	Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 151, 102992	7	11
73	First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103198	7	11
72	Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study. <i>Breast Cancer Research and Treatment</i> , 2020 , 182, 401-409	4.4	10
71	Targeting fibroblast growth factor receptor pathway in breast cancer. <i>Current Opinion in Oncology</i> , 2015 , 27, 452-6	4.2	10
70	Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety. <i>Molecular and Clinical Oncology</i> , 2018 , 9, 255-263	1.6	10
69	Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study. <i>Clinical Breast Cancer</i> , 2017 , 17, 559-563	3	9
68	It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature. <i>BMC Cancer</i> , 2018 , 18, 146	4.8	9
67	In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 3091-100	6.1	9

66	EMPACT syndrome associated with phenobarbital. <i>Dermatitis</i> , 2013 , 24, 37-9	2.6	7
65	Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. <i>Anti-Cancer Drugs</i> , 2009 , 20, 277-80	2.4	7
64	Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers. <i>Oncologist</i> , 2020 , 25, e1509-e1515	5.7	7
63	High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial. <i>Medicine (United States)</i> , 2018 , 97, e11254	1.8	7
62	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 1458-1467	21.7	7
61	Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study. <i>Anti-Cancer Drugs</i> , 2015 , 26, 117-22	2.4	6
60	Rapidly progressive disease in a castration-resistant prostate cancer patient after cabazitaxel discontinuation. <i>Anti-Cancer Drugs</i> , 2015 , 26, 236-9	2.4	6
59	Assessment of Total, PTEN, and AR-V7 Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e286-e298	3.3	6
58	Is There a Standard Chemotherapeutic Regimen for Hormone-Refractory Prostate Cancer? Present and Future Approaches in the Management of the Disease. <i>Tumori</i> , 2003 , 89, 349-360	1.7	5
57	Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. <i>Oncotarget</i> , 2020 , 11, 2083-2091	3.3	5
56	Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era. <i>ESMO Open</i> , 2020 , 5, e000885	6	5
55	Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials. <i>Gynecologic Oncology</i> , 2019 , 154, 83-88	4.9	4
54	The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Cancer</i> , 2017 , 8, 2663-2668	4.5	4
53	Time required to start multicentre clinical trials within the Italian Medicine Agency programme of support for independent research. <i>Journal of Medical Ethics</i> , 2015 , 41, 799-803	2.5	4
52	Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?. <i>Journal of Neuro-Oncology</i> , 2010 , 100, 311-9	4.8	4
51	EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. <i>Breast Cancer Research</i> , 2020 , 22, 83	8.3	4
50	Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists 2020 , 8,		4
49	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021 , 13,	6.6	4

48	Clinical features and psychological aspects of the decision-making process in stage I testicular germ cell tumors. <i>Future Oncology</i> , 2018 , 14, 1591-1599	3.6	4
47	Treatment options in HR+/HER2? advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us?. <i>Future Oncology</i> , 2015 , 11, 975-81	3.6	3
46	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. <i>European Journal of Cancer</i> , 2020 , 136, 43-51	7.5	3
45	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. <i>Breast</i> , 2020 , 50, 56-63	3.6	3
44	Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. <i>Oncolmmunology</i> , 2013 , 2, e25123	7.2	3
43	Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials. <i>Experimental and Therapeutic Medicine</i> , 2011 , 2, 449-455	2.1	3
42	FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920947970	5.4	3
41	Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABITUDE study. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920968725	5.4	3
40	A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103191	7	3
39	A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA. <i>Frontiers in Oncology</i> , 2020 , 10, 602153	5.3	3
38	Case Report: Detection of a Novel Germline Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie. <i>Frontiers in Oncology</i> , 2021 , 11, 602523	5.3	3
37	Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer. <i>Hereditary Cancer in Clinical Practice</i> , 2016 , 14, 18	2.3	2
36	Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues. <i>Breast Journal</i> , 2019 , 25, 1310-1311	1.2	2
35	Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology?. <i>International Journal of Biological Markers</i> , 2017 , 32, e474-e477	2.8	2
34	Using cumulative toxicity to identify the optimal second-line targeted therapy in patients with metastatic renal cell carcinoma: what's new?. <i>Future Oncology</i> , 2014 , 10, 845-50	3.6	2
33	Issues of banking breast cancer cells to generate mammospheres. <i>Cell and Tissue Banking</i> , 2013 , 14, 153-82		2
32	Cancer prevalence in the city of Naples: Contribution of the GP database analyses to the cancer registries network. <i>Molecular and Clinical Oncology</i> , 2013 , 1, 726-732	1.6	2
31	Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors. <i>Experimental and Therapeutic Medicine</i> , 2010 , 1, 611-617	2.1	2

30	Authors reply: an adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1079-1080	4	2
29	Long term deficiency of vitamin D in germ cell testicular cancer survivors. <i>Oncotarget</i> , 2018 , 9, 21078-21085	9.5	2
28	The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018 , 18, 832-836	2.2	2
27	Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature. <i>Medicine (United States)</i> , 2016 , 95, e2754	1.8	2
26	Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma: chemotherapy in malignant gastrointestinal neuroectodermal tumour. <i>Anti-Cancer Drugs</i> , 2019 , 30, 959-963	2.4	2
25	Epigenetic Silencing of Tracks the Acquisition of the Notch1-EGFR Signaling in a Xenograft Model of CD44/CD24/CD90 Myoepithelial Cells. <i>Molecular Cancer Research</i> , 2019 , 17, 628-641	6.6	2
24	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
23	PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study. <i>Medicine (United States)</i> , 2017 , 96, e6817	1.8	1
22	Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study. <i>BMC Cancer</i> , 2020 , 20, 232	4.8	1
21	Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a analysis from the adjuvant TOSCA trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835919899850	5.4	1
20	Combination of Cytotoxic Drugs for Patients with HER2-Negative Metastatic Breast Cancer. <i>Combination Products in Therapy</i> , 2013 , 3, 25-37		1
19	Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e13509-e13509	2.2	1
18	Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series. <i>Molecular and Clinical Oncology</i> , 2020 , 12, 456-460	1.6	1
17	Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis. <i>Oncotarget</i> , 2017 , 8, 112816-112824	3.3	1
16	Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study. <i>World Journal of Clinical Oncology</i> , 2021 , 12, 355-366	2.5	1
15	Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study. <i>Oncologist</i> , 2021 , 26, e1854-e1861	5.7	1
14	Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 103649	7	1
13	Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine. <i>Tumori</i> , 2013 , 99, e131-e133	1.7	0

12	Triple-negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e12549-e12549	2.2	o
11	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 82	7.8	o
10	Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 270-276	3.8	
9	Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study. <i>Oncologist</i> , 2013 , 18, 924-5	5.7	
8	Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy.. <i>Frontiers in Oncology</i> , 2021 , 11, 754108	5.3	
7	Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e12528-e12528	2.2	
6	Anti-EGFR target therapy in advanced thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8567-8567	2.2	
5	Breast cancer subtypes according to body mass index and insulin resistance.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 571-571	2.2	
4	Risk factors for cancer-related venous thromboembolism in ambulatory patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e20625-e20625	2.2	
3	Bevacizumab maintenance in metastatic colorectal cancer: How long?. <i>World Journal of Clinical Cases</i> , 2014 , 2, 717-23	1.6	
2	Pneumonitis in patients with thymoma and GoodS syndrome.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e20595-e20595	2.2	
1	Abstract P3-09-03: Single nucleotide polymorphisms of aromatase gene (CYP19A1) and toxicity of adjuvant aromatase inhibitors: A translational, prospective study. <i>Cancer Research</i> , 2022 , 82, P3-09-03-P3-09-03	10.1	